Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the colon or rectum * Unresectable disease * Metastatic or recurrent disease * Not amenable to potentially curative treatment * No untreated leptomeningeal or brain metastases PATIENT CHARACTERISTICS: Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 2,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * No known uncontrolled coagulopathy Hepatic * AST and ALT \< 2.5 times upper limits of normal (ULN) (5 times ULN if liver metastases are present) * Bilirubin \< 2.0 times ULN Renal * Creatinine clearance \> 40 mL/min * Urine protein negative * Urine protein:creatinine ratio \> 1 Cardiovascular * No unstable or uncontrolled hypertension (i.e., blood pressure \[BP\] \> 150/100 mm Hg despite antihypertensive therapy) * Patients who recently started or have adjusted antihypertensive medications are eligible provided BP is \< 140/90 mm Hg for ≥ 3 different measurements over 14 days * No arterial thromboembolic events within the past 6 months, including any of the following: * Transient ischemic attack * Cerebrovascular accident * Unstable angina * Myocardial infarction * Clinically significant peripheral vascular disease * No New York Heart Association class III-IV congestive heart failure * No uncontrolled symptomatic coronary artery disease or cardiac arrhythmia * No other significant uncontrolled cardiac disease Gastrointestinal * No lack of physical integrity of the upper gastrointestinal tract * No malabsorption syndrome * No inability to tolerate oral medication Immunologic * No prior severe infusion reaction to a monoclonal antibody * No history of an allergic reaction attributed to compounds of similar chemical or biologic composition to oxaliplatin, cetuximab, capecitabine, or bevacizumab * No prior unanticipated, severe reaction to fluoropyrimidine therapy or known hypersensitivity to fluoroucacil Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during the study and for 3-4 months after completion of study treatment * No peripheral neuropathy ≥ grade 2 * No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix * No known dihydropyrimidine dehydrogenase deficiency PRIOR CONCURRENT THERAPY: Biologic therapy * No prior adjuvant bevacizumab or cetuximab * No other concurrent anticancer immunotherapy or biologic therapy Chemotherapy * At least 6 months since a prior adjuvant fluorouracil-, leucovorin calcium-, or capecitabine-based regimen * At least 12 months since prior adjuvant oxaliplatin * No prior chemotherapy for metastatic or recurrent disease Endocrine therapy * No concurrent hormonal therapy Radiotherapy * No concurrent radiotherapy Surgery * More than 4 weeks since prior major surgery and recovered * More than 6 months since vascular surgery, stenting, or angioplasty Other * At least 4 weeks since prior and no concurrent sorivudine or brivudine * More than 4 weeks since prior participation in any investigational drug study * No prior therapy that affects or targets the epidermal growth factor pathway * No concurrent cimetidine * Concurrent ranitidine, famotidine, or proton-pump inhibitors allowed * Concurrent anticoagulation therapy with full-dose anticoagulant allowed provided dose is stable for at least 2 weeks